甲状腺眼病治疗的新时代
本文综述甲状腺眼病(TED)的发病机制与治疗现状,重点讨论胰岛素样生长因子-1受体(IGF-1R)拮抗抗体替妥木单抗。2期和3期随机安慰剂对照试验显示,替妥木单抗对中重度活动性TED患者有效且安全,更多患者获得突眼的有意义改善。
要点
- 替妥木单抗为全人源单克隆IGF-1R拮抗抗体,2期和3期随机安慰剂对照试验证实其对中重度活动性TED有效且安全。
- 2期和3期研究均显示,接受替妥木单抗的活动性TED患者中更多患者获得突眼的有意义改善。
- 现有TED治疗针对炎症和症状,不改变病程,突眼、斜视及复视常长期残留。
核心结论
- 靶向分子治疗替妥木单抗显示出疾病修饰获益,有可能转变TED的治疗范式。
- 现有TED治疗策略针对炎症和症状,但不改变疾病病程。
研究设计与样本
- 本文为视角(Perspective)文章,基于文献综述与作者经验。
- 文中引用的关键证据包括已完成的2期和3期随机、安慰剂对照试验。
主要发现
- 许多文献显示TED中IGF-1R过表达,其作为自身抗原被激活是TED发病的关键因素。
- 多项体外研究显示抑制IGF-1R可减弱下游分子事件,包括细胞因子和透明质酸产生及细胞分化。
- 2期和3期随机安慰剂对照试验证明替妥木单抗在中重度活动性TED患者中的疗效与安全性。
- 2期和3期研究结果均显示,接受替妥木单抗的活动性TED患者中更多患者获得突眼的有意义改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Improved understanding of thyroid eye disease (TED) pathogenesis has facilitated identification of a targeted molecular approach for TED treatment offering the potential to halt or slow disease progression in a nonsurgical manner. Herein, we provide a summary of the current knowledge of TED management, followed by discussion of a novel insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody and its potential to change the course of the disease. DESIGN: Perspective. METHODS: Review of the literature and authors' experience. RESULTS: Many publications demonstrate IGF-1R overexpression in TED, and its activation as an autoantigen as a critical factor in TED pathogenesis. Several in vitro studies demonstrate that IGF-1R inhibition attenuates downstream molecular events including cytokine and hyaluronan production, and cellular differentiation. These observations led to the hypothesis that blocking IGF-1R may abrogate the clinical progression of TED. The recent completion of phase 2 and 3 randomized, placebo-controlled trials demonstrate the efficacy and safety of teprotumumab, a fully human monoclonal IGF-1R antagonist antibody, in patients with moderate-to-severe, active TED. Both the phase 2 and the recent phase 3 study results demonstrate that more patients with active TED receiving teprotumumab experienced a meaningful improvement in proptosis. CONCLUSIONS: Current TED treatment strategies target inflammation and symptoms, but do not modify the disease course. Therefore, proptosis as well as strabismus and its resulting diplopia often remain, impacting patient well-being and quality of life over the long term. Targeted molecular therapy using teprotumumab demonstrates disease-modifying benefits with the potential to shift the paradigm for TED treatment.
引用
- Patel A, Yang H, Douglas RS, et al. A New Era in the Treatment of Thyroid Eye Disease. Am J Ophthalmol. 2019. PMID: 31377284. doi:10.1016/j.ajo.2019.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。